Emergent BioSolutions, Inc. (EBS)
6.21
-0.02
(-0.32%)
USD |
NYSE |
Sep 04, 16:00
6.21
0.00 (0.00%)
Pre-Market: 20:00
Emergent BioSolutions SG&A Expense (TTM) : 181.20M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 181.20M |
| March 31, 2026 | 180.30M |
| December 31, 2025 | 186.10M |
| September 30, 2025 | 195.80M |
| June 30, 2025 | 233.50M |
| March 31, 2025 | 275.70M |
| December 31, 2024 | 308.00M |
| September 30, 2024 | 336.90M |
| June 30, 2024 | 346.30M |
| March 31, 2024 | 351.80M |
| December 31, 2023 | 368.40M |
| September 30, 2023 | 372.90M |
| June 30, 2023 | 368.70M |
| March 31, 2023 | 358.40M |
| December 31, 2022 | 341.90M |
| September 30, 2022 | 341.90M |
| June 30, 2022 | 342.20M |
| March 31, 2022 | 352.30M |
| December 31, 2021 | 348.40M |
| September 30, 2021 | 336.30M |
| June 30, 2021 | 329.70M |
| March 31, 2021 | 314.50M |
| December 31, 2020 | 303.30M |
| September 30, 2020 | 293.40M |
| June 30, 2020 | 282.90M |
| Date | Value |
|---|---|
| March 31, 2020 | 277.70M |
| December 31, 2019 | 273.40M |
| September 30, 2019 | 282.20M |
| June 30, 2019 | 259.30M |
| March 31, 2019 | 228.01M |
| December 31, 2018 | 202.82M |
| September 30, 2018 | 163.79M |
| June 30, 2018 | 156.19M |
| March 31, 2018 | 148.55M |
| December 31, 2017 | 143.50M |
| September 30, 2017 | 136.88M |
| June 30, 2017 | 143.06M |
| March 31, 2017 | 147.12M |
| December 31, 2016 | 143.68M |
| September 30, 2016 | 143.21M |
| June 30, 2016 | 128.32M |
| March 31, 2016 | 128.85M |
| December 31, 2015 | 131.63M |
| September 30, 2015 | 128.65M |
| June 30, 2015 | 133.14M |
| March 31, 2015 | 127.24M |
| December 31, 2014 | 122.84M |
| September 30, 2014 | 116.34M |
| June 30, 2014 | 108.00M |
| March 31, 2014 | 97.94M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Exelixis, Inc. | 533.92M |
| Capricor Therapeutics, Inc. | 35.43M |
| ADMA Biologics, Inc. | 103.25M |
| Akebia Therapeutics, Inc. | 117.15M |
| Arcutis Biotherapeutics, Inc. | 297.60M |